The estimated Net Worth of Steve H Kanzer is at least $10.2 Milhão dollars as of 30 April 2014. Steve Kanzer owns over 5,003,025 units of Theriva Biologics Inc stock worth over $2,239,399 and over the last 10 years Steve sold SYN stock worth over $7,917,351.
Steve has made over 2 trades of the Theriva Biologics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Steve sold 5,003,025 units of SYN stock worth $7,154,326 on 30 April 2014.
The largest trade Steve's ever made was selling 5,003,025 units of Theriva Biologics Inc stock on 30 April 2014 worth over $7,154,326. On average, Steve trades about 2,633,069 units every 1 days since 2014. As of 30 April 2014 Steve still owns at least 2,195,489 units of Theriva Biologics Inc stock.
You can see the complete history of Steve Kanzer stock trades at the bottom of the page.
Steve's mailing address filed with the SEC is C/O PHARMAINVESTORS LLC, 9045 LA FONTANA BLVD., STE. 238, BOCA RATON, FL, 33434.
Over the last 12 years, insiders at Theriva Biologics Inc have traded over $8,016,723 worth of Theriva Biologics Inc stock and bought 6,682,900 units worth $10,572,593 . The most active insiders traders include Randal Jintrexon Corp Kirk, Steve H Kanzer, eScott Tarriff. On average, Theriva Biologics Inc executives and independent directors trade stock every 223 days with the average trade being worth of $899,000. The most recent stock trade was executed by Steven A Shallcross on 10 May 2021, trading 50,000 units of SYN stock currently worth $24,500.
Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
Theriva Biologics Inc executives and other stock owners filed with the SEC include: